Prescribing, Policies and Pathways
or
Medicine / Guideline | Indication | RAG rating | Document type | Place |
---|---|---|---|---|
Adalimumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Adalimumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Alcohol Related | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Amitriptyline | Irritable bowel syndrome (IBS) 2nd line unlicensed | Green | n/a | Hertfordshire and West Essex ICB |
Anal fissure | Anal fissure | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Bezlotoxumab | Clostridium difficile | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Bile salts malabsorption | Bile salts malabsorption | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Biologic and Biosimilar Medicines | Where indicated | n/a | Patient information | Hertfordshire and West Essex ICB |
Botulinum toxin type A | Focal spasticity, Hemi-facial spasm, Blepharospasm, Cervical dystonia, Frey’s syndrome, Chronic anal fissure, Dysphagia, Hirschsprung’s disease, Overactive bladder,Masseteric hypertrophy and temporomandibular disorders | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Budesonide - rectal (Budenofalk) | Ulcerative colitis | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Budesonide (Jorveza) | Inducing remission of eosinophilic oesophagitis | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Cholecystectomy | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Co-danthramer | Constipation - restricted to constipation in terminally ill patients of all ages | Green | Decision document | Hertfordshire and West Essex ICB |
Colesevelam 2nd line | Diarrhoea associated with bile acid malabsorption | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Colestyramine 1st line | Diarrhoea associated with bile acid malabsorption | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Crohn's disease | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Darvadstrocel | Complex perianal fistulas in Crohns disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dicycloverine | Irritable bowel syndrome (IBS) | Double Red | n/a | Hertfordshire and West Essex ICB |
Diltiazem ointment 3rd line | Anal fissures | Green | n/a | Hertfordshire and West Essex ICB |
Docusate sodium | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Dupilumab | Eosinophilic oesophagitis | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Etrasimod | Ulcerative Colitis - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Faecal Immunochemical Test (FIT) process pathway for suspected Lower GI Cancer | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Filgotinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Glyceryl trinitrate ointment 2nd line | Anal fissures | Green | n/a | Hertfordshire and West Essex ICB |
Golimumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Hyoscine butylbromide | Irritable bowel syndrome (IBS) 1st line | Green | n/a | Hertfordshire and West Essex ICB |
Inflammatory Bowel Disease (IBD) | n/a | Clinical pathways | East and North Hertfordshire | |
Infliximab IV | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Infliximab IV | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Infliximab IV biosimilar | Diarrhoea or colitis associated with Immune Checkpoint Inhibitor therapy | Red | Decision document | Hertfordshire and West Essex ICB |
Ispaghula husk (Fybogel) | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Lactulose | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Laxido | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Liver Function Test (LFT) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Loperamide | Diarrhoea | Green | n/a | Hertfordshire and West Essex ICB |
Macrogol | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Mebeverine - immediate release (IR) | Irritable bowel syndrome (IBS) 1st line | Green | n/a | Hertfordshire and West Essex ICB |
Mebeverine - modified release (MR) | Irritable bowel syndrome (IBS) | Double Red | n/a | Hertfordshire and West Essex ICB |
Mesalazine - Octasa preferred 1st choice | Inflammatory bowel disease | Green | n/a | Hertfordshire and West Essex ICB |
Mesalazine -Mezavant | Inflammatory bowel disease | Double Red | n/a | Hertfordshire and West Essex ICB |
Methylnaltrexone bromide | Opioid induced bowel dysfunction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Methylnaltrexone bromide | Constipation - opioid induced | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Mirikizumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Naldemedine | Constipation - opioid induced | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Naloxegol | Constipation - opioid induced | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Non-Alcoholic Fatty Liver Disease (NAFLD) | n/a | Clinical pathways | East and North Hertfordshire | |
Obeticholic acid | Primary biliary cholangitis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Opioid Induced Constipation | Opioid Induced Constipation | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Ozanimod | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Paediatric Abdominal Pain | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Paediatric Constipation | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Paediatric Diarhoea and Vomitting | n/a | n/a | Hertfordshire and West Essex ICB | |
Peppermint oil | Irritable bowel syndrome (IBS) 1st line | Green | n/a | Hertfordshire and West Essex ICB |
Phosphate enema (Cleen) | Constipation | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Prednisolone | All indications - soluble tablet | n/a | Patient information | Hertfordshire and West Essex ICB |
Prednisolone enteric coated | All indications | Double Red | n/a | Hertfordshire and West Essex ICB |
Probiotics | Treatment or prevention of diarrhoea of any cause. | Double Red | Decision document | Hertfordshire and West Essex ICB |
Probiotics | Irritable bowel syndrome (IBS) | Double Red | n/a | Hertfordshire and West Essex ICB |
Proton pump inhibitors - paediatric | Gastro-protection | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Rifaximin | Hepatic encephalopathy | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Risankizumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Selective serotonin reuptake inhibitors (SSRIs) | Irritable bowel syndrome (IBS) 3rd line unlicensed | Green | n/a | Hertfordshire and West Essex ICB |
Senna | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Sucralfate | Gastrointestinal ulcers | Double Red | Decision document | Hertfordshire and West Essex ICB |
Tofacitinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Transanal irrigation | Bowel dysfunction | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Ulcerative colitis | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Upadacitinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Upadacitnib | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Ustekinumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Ustekinumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Vedolizumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Vedolizumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |